Now, however, as his fans adjust to the fact he won't be on the grid next season, Perez has continued to show off the advertising and marketing power he has with a blockbuster announcement on his ...
Eli Lilly's second candidate on the blockbuster list is a monoclonal antibody targeting the p19 subunit of IL-23, heading for a first-in-class approval in ulcerative colitis and third place for IL ...